



BIODIEM LTD  
ABN 20 096 845 993

Level 10, South Tower,  
459 Collins Street,  
Melbourne, Victoria, 3000  
Australia

Phone: +61 3 9613 4100  
Fax: +61 3 9613 4111  
Email: [info@biodiem.com](mailto:info@biodiem.com)  
Web: [www.biodiem.com](http://www.biodiem.com)

## ASX Announcement

### BioDiem Replaces Nobilon as Licensor of LAIV Technology to the World Health Organization

**Melbourne, 1 August 2011:** Australian biopharmaceutical development company BioDiem Ltd (ASX: BDM) today announced that it has entered into a licence agreement with the World Health Organization (WHO) for the LAIV influenza technology. With this agreement, BioDiem contributes to the WHO's Global Pandemic Influenza Action Plan by supporting the transfer of an egg-based live attenuated influenza vaccine (LAIV) production technology to developing country manufacturers.

The agreement replaces the LAIV licence granted to the WHO by Nobilon International B.V. in 2009. The agreement is a non-exclusive licence designed to support wider distribution of the live attenuated influenza vaccine in developing countries. Whereas public sector usage under this agreement is royalty-free, royalties will flow to Biodiem directly from private sector sales. As announced on 16 December 2010, BioDiem has already received US\$248,310 in royalty payments through sales of Nasovac™ into the Indian private market by the Serum Institute of India.

BioDiem's CEO, Julie Phillips, said 'BioDiem and its partner, the Institute of Experimental Medicine in Russia, have always maintained an excellent relationship with the WHO so it is of great benefit to us to have a more direct relationship with the WHO and to assist further access to the LAIV in developing countries in both public and private markets. BioDiem is also pleased to provide some funding to support the establishment of a back-up laboratory facility to provide reassortants to the WHO and its developing country licensees.'

---

## About BioDiem Ltd

BioDiem is an ASX-listed company, based in Melbourne, with an international focus on finding, adding value to and commercialising world-class research for vaccines, infectious diseases and other therapeutic areas. The company uses a cost-efficient approach to drug development through collaborations with academic centres of excellence, contract research organizations and partnerships with international pharmaceutical companies.

BioDiem's leading product is the Live Attenuated Influenza Vaccine (LAIV) technology, a novel intranasal vaccine being developed to prevent infection from seasonal and pandemic influenza. The technology was licensed to BioDiem by the Institute of Experimental Medicine in St Petersburg. It has also been launched in India as Nasovac for protection against H1N1 influenza. For additional information, please visit [www.biodiem.com](http://www.biodiem.com)

## Contact

### COMPANY

Julie Phillips - Chief Executive Officer  
BioDiem Ltd  
Ph: +61 3 9613 4100  
Email: [jphillips@biodiem.com](mailto:jphillips@biodiem.com)

### MEDIA & INVESTOR RELATIONS

Fay Weston - Director  
Talk Biotech  
Ph: +61 2 4885 2662 or 0422 206036  
Email: [fayweston@talkbiotech.com.au](mailto:fayweston@talkbiotech.com.au)